Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Randomized Phase III Trial of I.V. Vinflunine Plus Best Supportive Care as Second Line Therapy Versus Best Supportive Care After a Platinum-containing Regimen, in Patients With Advanced Transitional Cell Carcinoma of Urothelial Tract

NCT00315237 is registered in ClinicalTrials.gov with Pierre Fabre Medicament as lead sponsor.

NCT NCT00315237
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00315237 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Randomized Phase III Trial of I.V. Vinflunine Plus Best Supportive Care as Second Line Therapy Versus Best Supportive Care After a Platinum-containing Regimen, in Patients With Advanced Transitional Cell Carcinoma of Urothelial Tract
Lead sponsor
Pierre Fabre Medicament
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2005
Completion date
January 31, 2008
Enrollment
364 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, bladder neoplasms, transitional cell carcinoma of the urothelial tract